Oric Pharmaceuticals stock falls 6.48% amid bearish momentum as Oric Pharmaceuticals honors cancer survivors

Traders Union
All News
Business & Wealth
Companies
Oric Pharmaceuticals down 6.48% today

Highlights

ORIC Pharmaceuticals trades in a sustained downtrend below all major moving averages, reflecting persistent bearish momentum.
Bearish momentum is reinforced by negative signals from MACD and ADX, with several oscillators indicating an oversold but weak environment.
Price is projected to remain under pressure in the $7.00–$8.10 range next week, with a break below $7.00 likely leading to new lows.

Oric Pharmaceuticals stated it is advancing therapies designed to overcome resistance in cancer and expand possibilities for patients.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Broad downside pressure as price holds below all major averages

ORIC Pharmaceuticals is trading well below its key moving averages, with the current price of $7.50 sitting underneath the MA-20 at $8.34, the MA-50 at $9.42, and the MA-200 at $10.78. This positioning signals strong downward pressure across short, medium, and long-term timeframes. The Ichimoku Kijun level on D1 is $8.73, which stands as immediate resistance. Near-term support is at the MA-20 ($8.34), with key support at the MA-50 ($9.42), while the Kijun ($8.73) and MA-100 ($10.55) form immediate and key resistance levels, respectively.

Firmly negative momentum as oversold signals and volatility deepen

Momentum readings are firmly bearish, with both MACD and ADX on D1 pointing to continued downside and weak directional strength. Multiple oscillators, including RSI (35.75), Stoch RSI, and CCI, all highlight oversold conditions. BBP shows the sellers remain firmly in control intraday. The Awesome Oscillator is negative, further supporting the prevailing downtrend. ORIC has fallen $0.95 (11.24%) over the past week, now trading at $7.50, down from $8.45 a week ago. The price is currently at the very bottom of the weekly range, and weekly volatility stands at 24.73%, underscoring a clear, steady decline from recent highs. In today’s session, the share is down 6.48%, deepening the negative weekly momentum.

Low upside odds as range stabilizes near multi-month lows

Looking ahead, the expected price range for the coming week is $7.00 to $8.10, adjusted to reflect the weekly volatility and retain proximity to the current price and recent lows. Probability of a price increase is very low (less than 20%), while a further decline is much more likely, supported by Sell signals on RSI-W1, MACD-W1, and MA-50-W1. The baseline scenario is for ORIC to move sideways near recent support, reflecting potential oversold stabilization. A bullish scenario would require a break above $8.10, overcoming the Kijun and moving averages, though momentum indicators make this unlikely. In the bearish scenario, a drop below $7.00 could open room for further losses toward or even below the 52-week low of $7.32 but still comfortably above the annual floor. This short-term range remains anchored in the lower portion of the yearly band, far from the 52-week high of $14.93.

Earlier, analysts noted that Oric Pharmaceuticals was experiencing persistent bearish momentum amid heavy selling pressure. This article adds a fresh perspective on whether that downward trend will continue, with investors advised to watch for signs of stabilization or further decline as a key determinant for near-term positioning.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.